Compare Innovative Industrial Properties Inc (IIPR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Zimmer Biomet Holdings Inc — how do they compare? Innovative Industrial Properties Inc trades at $51.94 (market cap $1.43B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 11.9× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays the higher dividend (14.64%). Which is the better fit depends on your goals — on Pluang, investors hold Innovative Industrial Properties Inc for 86 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| IIPR | ZBH | |
|---|---|---|
Market Cap | $1.43B | $16.95B |
Volume | 394,222 | 2,505,240 |
Sector | Real Estate | Health |
52-Week High | $64.67 | $103.98 |
52-Week Low | $44.58 | $79.58 |
Typical Hold Time | 86 Days | 89 Days |
Enterprise Value | $1.96B | $24.02B |
Dividend Yield | 14.64% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $51.83, up 1.17% on the day, with a bearish technical signal and mixed earnings history. The stock shows attractive valuation ratios, including a P/E of 11.75 and P/B of 0.83, but revenue declined to $265.96M in 2025. Recent news highlights a $245 million mezzanine loan commitment and a quarterly dividend of $1.90, underscoring its REIT structure and focus on cannabis real estate.
The outlook is cautious due to tenant defaults and dividend sustainability concerns, though the stock offers a high yield and potential regulatory catalysts. Risks include sector volatility and financial performance pressures, while analyst consensus leans hold with a $84.67 price target suggesting upside if operational stability improves.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
